USP 〈71〉 Sterility Testing Explained: What Pharmacies and Compounding Labs Need to Know

Quick Summary: USP 〈71〉 Sterility Tests is the pharmacopeial method that defines how sterile drug products are tested for viable microorganisms — membrane filtration or direct inoculation, two growth media, and a 14-day incubation. It is not a sterilization validation standard, and it is not the test most compounding facilities run in-house. This guide separates the three controls that are routinely confused — the 〈71〉 compendial test, sterilization process validation to ISO 17665 with ISO 11138 biological indicators, and routine biological indicator monitoring — and shows Canadian pharmacies, compounding labs and manufacturers where each one applies.

Quick Facts

What USP 〈71〉 Actually Is

USP 〈71〉 Sterility Tests is a general chapter of the United States Pharmacopeia–National Formulary that specifies the test methods used to determine whether a pharmacopeial article complies with the requirement to be sterile. Its methods have been harmonized with the corresponding chapters of the European Pharmacopoeia and the Japanese Pharmacopoeia, which is why a sterility test protocol written in one jurisdiction is largely transferable to another.

Two things about 〈71〉 cause most of the confusion in compounding facilities. First, it is a test of the finished product — a sample of the article is incubated and observed for microbial growth. Second, it does not tell you whether your autoclave works. A sterilizer can pass a sterility test on Monday and fail to penetrate a dense load on Friday. That is why process validation and routine monitoring exist as separate controls, and why they are performed with biological indicators rather than with the 〈71〉 test.

Membrane filtration vs direct inoculation

The two media are not interchangeable. Fluid Thioglycollate Medium supports anaerobic growth and is incubated at 30–35 °C; Soybean–Casein Digest Medium (often referred to as tryptic soy broth) supports aerobic bacteria and fungi and is incubated at 20–25 °C. Both are run in parallel. Before any of this is valid, the laboratory must perform a method suitability test — often called a bacteriostasis or fungistasis test — to prove that the product itself does not suppress growth under the test conditions.

Who Has to Run Sterility Testing in Canada

The obligation depends on what your facility makes, not on what equipment you own. Four groups come up repeatedly.

One point that surprises compounding staff: 〈71〉 is a compendial method, and running it in-house requires a microbiology laboratory and a validated method for each product type. Most Canadian compounding pharmacies do not run 〈71〉 themselves — they outsource it to an accredited contract laboratory, where the 14-day incubation and the associated cost become part of the release timeline.

The Three Controls That Get Confused

Pharmacy and laboratory teams routinely use the phrase "sterility testing" to describe three different activities. Getting the vocabulary right is what makes an inspection go smoothly.

The distinction matters commercially as well as technically. A USP 〈71〉 test is not a consumable you can buy — it is a service performed by a laboratory. What a facility buys and runs itself is the biological indicator that supports validation and routine monitoring, and that product category comes in different formats, organisms and readout times.

Where Biological Indicators Fit

A biological indicator (BI) is a prepared, standardized population of resistant bacterial spores that is exposed to the sterilization process and then incubated to see whether anything survived. For moist heat sterilization the organism is Geobacillus stearothermophilus, carried at a population typically between 10⁵ and 10⁶ spores per carrier and defined by its D-value — the time required to reduce the population by one log at a stated temperature.

ISO 11138-1 sets the general requirements for biological indicators, their production, labelling and performance testing; ISO 11138-3 does the same specifically for moist heat. ISO 17665 describes how a moist heat sterilization process is developed, validated and routinely controlled. Together these standards are what an inspector means when asking to see sterilization validation records — and they are why a pass on a chemical indicator, which responds to process parameters, is not a substitute for a BI, which responds to actual microbial kill.

Validating a cycle: the short version

A typical steam validation for a pharmacy autoclave follows a sequence: establish the load configuration and the cold spot; confirm air removal and steam quality, for example with a Bowie-Dick test on pre-vacuum units; place BI challenges in the load; run the cycle; incubate the BIs and record results; then repeat across three consecutive cycles to demonstrate reproducibility. The common pharmacy cycles referenced in this work are 121 °C for 15–30 minutes on gravity-displacement units and 132–134 °C for about 3–4 minutes on pre-vacuum units, with the exact parameters set by the load and the equipment manufacturer.

Routine monitoring then continues with a BI in every load that contains implantable or high-risk items, and on whatever schedule the facility's SOP defines for other loads. Under the NAPRA model standards the expectation is that sterilization processes are validated and monitored rather than assumed. Facilities should confirm the specific frequency with their provincial regulator and accreditation body, because provincial requirements differ.

Choosing a Biological Indicator for a Sterile Facility

Once the framework is clear, the purchasing decision comes down to five variables.

Per-test cost is where formats hide reality. CliniEco Medical publishes Canadian pricing rather than requiring a quote: the 24-hour biological indicator 25-pack at $59.99 works out to roughly $2.40 per test, and the 3-hour rapid fluorescence BI 50-pack at $199.99 to about $4.00 per test. Both are ISO 11138-1 and -3 compliant steam indicators carrying Geobacillus stearothermophilus ATCC 7953. The 24-hour line runs in a standard 55–60 °C dry-block incubator, and the rapid line pairs with a 4-well fluorescence reader — neither locks a facility into a single BI brand.

That last point deserves emphasis for anyone building a supply plan. ISO 11138 defines performance, not brand. A facility that documents the organism, population, D-value and format can source compliant BIs from more than one supplier, which protects the monitoring programme from single-source disruption without reopening the validation.

Common Compliance Gaps

Four gaps appear repeatedly when sterile facilities review their documentation.

For facilities in the United States, or exporting there, 21 CFR 211.113 sets the corresponding expectation that sterilization processes be validated. Canadian and US requirements converge on the same practical point: the BI record is the evidence.

Frequently Asked Questions

What is USP 〈71〉 sterility testing?

USP 〈71〉 Sterility Tests is a general chapter of the United States Pharmacopeia that defines the test methods used to determine whether a pharmacopeial article required to be sterile actually is sterile. It specifies two methods — membrane filtration and direct inoculation — two growth media incubated at different temperatures, and a 14-day incubation period. The methods are harmonized with the European and Japanese pharmacopoeias.

Is USP 〈71〉 the same as a biological indicator test?

No. USP 〈71〉 tests a sample of the finished product for the presence of viable microorganisms. A biological indicator is a standardized spore population used to validate and routinely monitor the sterilization process itself, under ISO 11138 and ISO 17665. One answers whether the product is sterile; the other answers whether the sterilizer reliably sterilizes.

Do Canadian compounding pharmacies have to run USP 〈71〉?

Canadian sterile compounding is governed primarily by the NAPRA model standards as enforced by each provincial pharmacy regulator, with USP 〈797〉 as the widely used international reference. Those standards require validated sterilization and testing of finished preparations. Whether that testing follows the 〈71〉 method depends on the preparation and the provincial framework; most pharmacies send samples to an accredited contract laboratory rather than maintaining a sterility-testing laboratory on site.

How long does a USP 〈71〉 sterility test take?

The standard incubation is 14 days, during which the inoculated media are observed for growth. That incubation period, plus laboratory queue time, is why sterility testing is usually a release-timeline consideration rather than a same-day check.

Which organism is used in a steam biological indicator?

Geobacillus stearothermophilus, typically at a population of 10⁵ to 10⁶ spores per carrier. Dry heat and ethylene oxide processes use Bacillus atrophaeus. The organism is chosen for its resistance to the specific sterilization process being monitored.

Can a compounding facility do sterility testing in-house?

It is possible but uncommon. USP 〈71〉 requires a controlled microbiology environment, validated methods for each product type, growth-promotion testing of media and a method suitability test. Most Canadian compounding operations outsource the test and keep the in-house programme focused on what they can run daily — validated sterilization with biological indicators and routine monitoring.

Does CliniEco Medical hold a Health Canada establishment licence?

Yes. CliniEco Medical is a licensed medical device establishment (MDEL #35334).

Related Reading

• Sterilization Compliance Hub — monitoring requirements across healthcare and industry
• Sterility Assurance Level (SAL) explained: what 10^-6 means for sterilization
• QC laboratory supplies: sterility testing consumables in Canada
• 3M Attest 1291 vs 1292 vs 1492V: is a rapid steam BI worth it?
• Raven Biological Laboratories ProSpore SCBIs and steam validation sourcing
• Sterilization monitoring collection — biological indicators, incubators and readers

Last updated: September 2026. CliniEco Medical is a licensed medical device establishment (MDEL #35334). Sterilization monitoring products referenced here are supplied under ISO 11138-1 and -3 compliance documentation, available on request.

Sources

1. United States Pharmacopeia (2017). General Chapter 〈71〉 Sterility Tests. USP–NF
2. United States Pharmacopeia. General Chapter 〈797〉 Pharmaceutical Compounding—Sterile Preparations
3. USP — General Chapter 〈797〉 (compounding resources)
4. NAPRA — Model Standards for Pharmacy Compounding of Non-hazardous Sterile Preparations
5. NAPRA — Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations
6. Health Canada — Guidance on medical device establishment licensing (GUI-0016)
7. Health Canada — Annex 1: Good manufacturing practices for the manufacture of sterile drugs (GUI-0119)
8. Health Canada — Good manufacturing practices guide for drug products (GUI-0001)
9. Medical Devices Regulations, SOR/98-282 (Justice Laws)
10. ISO 11138-1:2017 — Sterilization of health care products — Biological indicators — Part 1: General requirements
11. ISO 11138-3:2017 — Biological indicators for moist heat sterilization processes
12. ISO 17665:2024 — Sterilization of health care products — Moist heat
13. 21 CFR 211.113 — Control of microbiological contamination
14. CDC — Disinfection and sterilization (infection control guidance)
15. Submerged bioreactor production of Geobacillus stearothermophilus ATCC 7953 spores for biological indicators
16. Health Canada — Medical devices